Safety and Antitumour Activity of Setidegrasib in Patients with Previously Treated Advanced KRAS p.G12D-mutated NSCLC and PADC By Ogkologos - April 13, 2026 254 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a first-in-human phase I study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Opinion: ‘We’re making headway, but we can’t be complacent’ February 11, 2021 FDA Approves Tisagenlecleucel for Relapsed or Refractory Follicular Lymphoma June 24, 2022 A Vaccine to Treat Non-Hodgkin Lymphoma Advancing in Clinical Trials May 7, 2019 Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 Load more HOT NEWS Aiming to Prevent Cancer Cases, ESMO Calls Against Misleading Alcohol-Labelling Following... Exercising While Living With Peripheral Neuropathy: What People Diagnosed With Cancer... NCI Launches New Resource for Specimens and Data from Cancer Clinical... Lung Cancer Treatment Research Enters a New Era
